Top 10 Wall Street Losers of 2016
These Companies Lost the Most in a Down Year for Biopharma Stocks
Reading miRNAs for Clinical Meaning
Single miRNAs Don’t Say Much, but They May Become Eloquent Biomarkers if We Take Their Testimony in Context
Sorting Out the CRISPR Patent Case
Sounds of Science Podcast
Good Assays for Bad Immunogenicity
Avoid “Bad” Immunogenicity by Using Assays That Are More Sensitive and Can Adapt to Increasingly Complex and Specialized Drugs
For full access to this article login to GEN Select now.
Myriad Options for Molecular Diagnostics
As Technology Advances through the Clinical Arena, Costs Are Lowered and Time Is Saved
- Biomarkers save money. That simple fact, coupled with a wealth of information to link specific diseases to particular biomarkers, is resulting in explosive growth for molecular diagnostics. “Molecular diagnostics is proving it can significantly lower the cost and overall Leomics Associates and scientific advisor for CytoCare. Starting patients ...
Not registered yet? Please fill out the form below and enjoy complimentary access to this and an exclusive collection of premium content and personalization features as a GEN Select insider. Learn More.
Get GEN Select Access Now
- Do not put any letters or characters here if you are not a spy program.